SLX1B-SULT1A4

Across TCGA pan-cancer cohorts, SLX1B-SULT1A4 RNA differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of SLX1B-SULT1A4’s most consistent transcriptional readouts.

The strongest signal is observed in breast invasive carcinoma (BRCA), where SLX1B-SULT1A4 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types SLX1B-SULT1A4 is over-expressed in tumor.

BRCA, STAD, and LUSC are the cancer types where SLX1B-SULT1A4 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SLX1B-SULT1A4 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BRCA	All	All	+0.007	<.001	6	view →
STAD	Male	All	+0.014	.006	5	view →
LUSC	Male	II,III,IV	+0.016	.011	4	view →
HNSC	Male	II,III,IV	+0.005	.027	4	view →
BLCA	All	All	+0.009	.045	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

SLX1B-SULT1A4–BRCA

Open the BRCA breakdown →